Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Ann Pharmacother ; 50(10): 832-9, 2016 10.
Artículo en Inglés | MEDLINE | ID: mdl-27371544

RESUMEN

BACKGROUND: The optimal regimen for pharmacological prophylaxis of venous thromboembolism (VTE) in underweight, critically ill patients is unknown. OBJECTIVE: To describe prescribing patterns for VTE prophylaxis in underweight (≤50 kg or body mass index ≤18.5 kg/m(2)), critically ill patients and identify the prevalence of VTE and bleeding. METHODS: This was a retrospective cohort study that included patients who received standard- or reduced-dose VTE prophylaxis for ≥48 hours. RESULTS: A total of 295 individuals were included in the study. The majority of underweight patients in this study (79.7%) received unfractionated heparin, 5000 units 3 times daily. No statistically significant difference in the prevalence of clinically relevant VTEs between the reduced- and standard-dose groups was observed (4.4% vs 5.6%, P = 1.00), but a higher proportion of bleeding events was identified within the standard-dose group (6.7% vs 11.2%, P = 0.4). CONCLUSIONS: Empirical dose reductions of VTE prophylaxis are infrequently used in underweight, critically ill patients. Further studies need to be conducted that assess the safety and efficacy of reduced-dose VTE prophylactic regimens in this population to determine if acceptable efficacy can be achieved, with lower risks of bleeding.


Asunto(s)
Anticoagulantes/administración & dosificación , Heparina/administración & dosificación , Servicios Preventivos de Salud/métodos , Delgadez , Tromboembolia Venosa/prevención & control , Adulto , Anciano , Anticoagulantes/uso terapéutico , Enfermedad Crítica , Relación Dosis-Respuesta a Droga , Prescripciones de Medicamentos , Femenino , Hemorragia/inducido químicamente , Hemorragia/epidemiología , Heparina/uso terapéutico , Humanos , Masculino , Persona de Mediana Edad , Prevalencia , Estudios Retrospectivos , Factores de Riesgo
2.
Br J Oral Maxillofac Surg ; 48(6): 466-8, 2010 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-20129724

RESUMEN

Atypical fibroxanthoma is an unusual tumour of skin seen mainly in the head and neck region of elderly patients. Clinically it appears as red, ulcerated nodules, which can be difficult to differentiate from other tumours without histopathological examination. Immunohistochemical analysis also aids diagnosis. The mainstay of treatment is operation. We present a case series of 16 patients with 17 atypical fibroxanthomas over a 5-year period in a district general hospital.


Asunto(s)
Histiocitoma Fibroso Benigno/patología , Neoplasias Cutáneas/patología , Anciano , Anciano de 80 o más Años , Diagnóstico Diferencial , Femenino , Humanos , Masculino , Estudios Retrospectivos , Cuero Cabelludo/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA